T Joshi1, M Johnson, R Newton, M Giembycz. 1. Airways Inflammation Research Group, Department of Physiology and Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND AND PURPOSE: International asthma guidelines recommend that inhaled glucocorticoids be used as a monotherapy in all patients with mild to moderate disease because of their ability to suppress airways inflammation. Current evidence suggests that the therapeutic benefit of glucocorticoids is due to the transactivation and transrepression of anti-inflammatory and pro-inflammatory genes respectively. However, the extent to which clinically relevant glucocorticoids are equivalent in their ability to modulate gene expression is unclear. EXPERIMENTAL APPROACH: A pharmacodynamics investigation of glucocorticoid receptor (GR)-mediated gene transactivation in BEAS-2B human airway epithelial cells was performed using a glucocorticoid response element luciferase reporter coupled with an analysis of glucocorticoid-inducible genes encoding proteins with anti-inflammatory and adverse-effect potential. KEY RESULTS: Using transactivation as a functionally relevant output, a given glucocorticoid displayed a unique, gene expression 'fingerprint' where intrinsic efficacy and GR density were essential determinants. We showed that depending on the gene selected for analysis, a given glucocorticoid can behave as an antagonist, partial agonist, full agonist or even 'super agonist'. In the likely event that different, tissue-dependent gene expression profiles are reproduced in vivo, then the anti-inflammatory and adverse-effect potential of many glucocorticoids currently available as asthma therapeutics may not be equivalent. CONCLUSIONS AND IMPLICATIONS: The generation of gene expression 'fingerprints' in target and off-target human tissues could assist the rational design of GR agonists with improved therapeutic ratios. This approach could identify compounds that are useful in the management of severe asthma and other inflammatory disorders where systemic exposure is desirable.
BACKGROUND AND PURPOSE: International asthma guidelines recommend that inhaled glucocorticoids be used as a monotherapy in all patients with mild to moderate disease because of their ability to suppress airways inflammation. Current evidence suggests that the therapeutic benefit of glucocorticoids is due to the transactivation and transrepression of anti-inflammatory and pro-inflammatory genes respectively. However, the extent to which clinically relevant glucocorticoids are equivalent in their ability to modulate gene expression is unclear. EXPERIMENTAL APPROACH: A pharmacodynamics investigation of glucocorticoid receptor (GR)-mediated gene transactivation in BEAS-2B human airway epithelial cells was performed using a glucocorticoid response element luciferase reporter coupled with an analysis of glucocorticoid-inducible genes encoding proteins with anti-inflammatory and adverse-effect potential. KEY RESULTS: Using transactivation as a functionally relevant output, a given glucocorticoid displayed a unique, gene expression 'fingerprint' where intrinsic efficacy and GR density were essential determinants. We showed that depending on the gene selected for analysis, a given glucocorticoid can behave as an antagonist, partial agonist, full agonist or even 'super agonist'. In the likely event that different, tissue-dependent gene expression profiles are reproduced in vivo, then the anti-inflammatory and adverse-effect potential of many glucocorticoids currently available as asthma therapeutics may not be equivalent. CONCLUSIONS AND IMPLICATIONS: The generation of gene expression 'fingerprints' in target and off-target human tissues could assist the rational design of GR agonists with improved therapeutic ratios. This approach could identify compounds that are useful in the management of severe asthma and other inflammatory disorders where systemic exposure is desirable.
Authors: Mark Salter; Keith Biggadike; Joyce L Matthews; Michael R West; Michael V Haase; Stuart N Farrow; Iain J Uings; David W Gray Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-06-15 Impact factor: 5.464
Authors: Keith Biggadike; Randy K Bledsoe; Anne M Hassell; Barrie E Kirk; Iain M McLay; Lisa M Shewchuk; Eugene L Stewart Journal: J Med Chem Date: 2008-06-04 Impact factor: 7.446
Authors: Keith Biggadike; Randy K Bledsoe; Diane M Coe; Tony W J Cooper; David House; Marie A Iannone; Simon J F Macdonald; Kevin P Madauss; Iain M McLay; Tracy J Shipley; Simon J Taylor; Thuy B Tran; Iain J Uings; Victoria Weller; Shawn P Williams Journal: Proc Natl Acad Sci U S A Date: 2009-10-12 Impact factor: 11.205
Authors: Md Mostafizur Rahman; Nowshin N Rumzhum; Jonathan C Morris; Andrew R Clark; Nicole M Verrills; Alaina J Ammit Journal: Sci Rep Date: 2015-05-18 Impact factor: 4.379
Authors: Ebony R Fietz; Christine R Keenan; Guillermo López-Campos; Yan Tu; Cameron N Johnstone; Trudi Harris; Alastair G Stewart Journal: Sci Rep Date: 2017-03-06 Impact factor: 4.379
Authors: I H Heijink; M R Jonker; M de Vries; A J M van Oosterhout; E Telenga; N H T Ten Hacken; D S Postma; M van den Berge Journal: Respir Res Date: 2016-01-06